Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16494808 | 0.94 | ACHE (0.62) | ACHEMAPTALDH1A1ALOX5EPHX2 | |
| SCHEMBL16494249 | 0.92 | ACHE (0.55) | ACHEMAPTHDAC1HDAC6LMNA | |
| SCHEMBL16494169 | 0.92 | ACHE (0.56) | ACHEMAPTHDAC1HDAC6ALOX5 | |
| SCHEMBL16494587 | 0.90 | TAAR1 (0.60) | ACHEMAPTHDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL16494522 | 0.90 | NPC1 (0.61) | ACHEMAPTHDAC1HDAC6ALOX5 | |
| SCHEMBL16495028 | 0.88 | ACHE (0.56) | ACHEMAPTALDH1A1ALOX5EPHX2 | |
| SCHEMBL16494492 | 0.88 | ACHE (0.52) | ACHEHDAC1HDAC6ALDH1A1ADRB3 | |
| SCHEMBL16494639 | 0.87 | ACHE (0.62) | ACHEMAPTHDAC1HDAC6LMNA | |
| SCHEMBL16494058 | 0.86 | ACHE (0.61) | ACHEHDAC1HDAC6ADRB2ADRB1 | |
| SCHEMBL16494294 | 0.85 | ACHE (0.59) | ACHEADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | claimed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | claimed |
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | ACHE 2/4885MAPT 2067/4885HDAC1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.